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Abstract
Uterine smooth muscle tumors range from benign leiomyomas to malignant leiomyosarcomas. Based on numerous
molecular studies, leiomyomas and leiomyosarcomas mostly lack shared mutations and the majority of tumors are
believed to develop through distinct mechanisms. To further characterize the molecular variability among uterine
smooth muscle tumors, and simultaneously insinuate their potential malignant progression, we examined the
frequency of known genetic leiomyoma driver alterations (MED12 mutations, HMGA2 overexpression, biallelic FH
inactivation) in 65 conventional leiomyomas, 94 histopathological leiomyoma variants (18 leiomyomas with bizarre
nuclei, 22 cellular, 29 highly cellular, and 25 mitotically active leiomyomas), and 51 leiomyosarcomas. Of the 210
tumors analyzed, 107 had mutations in one of the three driver genes. No tumor had more than one mutation
confirming that all alterations are mutually exclusive. MED12 mutations were the most common alterations in
conventional and mitotically active leiomyomas and leiomyosarcomas, while leiomyomas with bizarre nuclei were
most often FH deficient and cellular tumors showed frequent HMGA2 overexpression. Highly cellular leiomyomas
displayed the least amount of alterations leaving the majority of tumors with no known driver aberration. Our
results indicate that based on the molecular background, histopathological leiomyoma subtypes do not only differ
from conventional leiomyomas, but also from each other. The presence of leiomyoma driver alterations in nearly
one third of leiomyosarcomas suggests that some tumors arise through leiomyoma precursor lesion or that these
mutations provide growth advantage also to highly aggressive cancers. It is clinically relevant to understand the
molecular background of various smooth muscle tumor subtypes, as it may lead to improved diagnosis and
personalized treatments in the future.
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Background
Uterine leiomyomas (ULs) are extremely common human
neoplasms that originate from the smooth muscle cells of
the myometrium. Due to their dependency on the ovarian
steroids estrogen and progesterone, ULs occur in women
of reproductive age and typically regress with the onset of
menopause [1]. The life time prevalence of ULs is
approximately 70% among white and more than 80%
among black women [2]. Despite their benign nature, ULs
can cause considerable morbidity, such as heavy and
prolonged menstrual flow, abdominal pain and discom-
fort, and reproductive dysfunction. They are also the
single most prevalent cause for hysterectomy and pose a
considerable socio-economic impact [3]. Based on histo-
pathology, ULs can be divided into conventional leio-
myomas and various relatively rare subtypes, such as
leiomyomas with bizarre nuclei, cellular, and mitotically
active leiomyomas [4]. Histopathological UL subtypes
explain approximately 10% of all ULs. Although these
subtypes mimic malignancy in one or more aspects, their
behavior is thought to be benign.
Approximately 40% of leiomyomas harbor non-random
cytogenetic rearrangements, of which the most common
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is a translocation between chromosome bands 12q15 and
14q24 leading to overexpression of high mobility group
AT-hook 2 (HMGA2) [5–7]. Other chromosomal al-
terations include, for example, interstitial deletions in 7q,
rearrangements of 6p21, and trisomy 12. Several inde-
pendent studies representing various ethnic groups have
shown that approximately 70% of ULs harbor specific mu-
tations in mediator complex subunit 12 (MED12) [8–11].
All observed changes have been missense or small in-
frame insertion-deletion mutations in exons 1 and 2,
affecting a highly conserved region of the gene. Subse-
quent studies have indicated that histopathological UL
subtypes harbor significantly fewer MED12 mutations
than conventional leiomyomas [12, 13]. Rarely, ULs can
be associated with a familial Hereditary Leiomyomatosis
and Renal Cell Cancer (HLRCC) syndrome. The syn-
drome is caused by heterozygous germline mutations in
fumarate hydratase (FH), which encodes an enzyme fu-
marase of tricarboxylic acid cycle [14]. Our recent high-
throughput sequencing efforts have pointed to at least
three distinct molecular subclasses among conventional
ULs, each candidate subclass displaying a characteristic
genetic driver aberration as well as unique global gene
expression profile: MED12 mutation-positive, HMGA2-
overexpressing, and FH-deficient ULs [15, 16].
Uterine leiomyosarcomas (ULMSs) are rare, malignant
smooth muscle tumors with a poor 5-year survival and
high recurrence rate [17–20]. The majority of ULMSs
occur in women >50 years of age with an annual inci-
dence of 0.3–0.4/100,000 women [21, 22]. The present-
ing symptoms of this tumor type greatly overlap with
those of benign ULs, making early diagnosis of ULMSs
difficult. Surgery is the recommended primary treat-
ment, yet the diagnosis is often made histologically after
the surgery. Even then, the clinical course of ULMS is
difficult to predict. Occasionally, diagnostic challenges
emerge in daily pathological practice in distinguishing
ULMSs from histopathological UL subtypes. The accur-
ate diagnosis has important prognostic and therapeutic
implications. Most ULMSs are aneuploid with complex
structural chromosomal alterations [23], however, no
consistent structural aberrations have been identified in
these tumors. So far, only a few genes have been associ-
ated with ULMSs, including TP53, RB1, ATRX, and
MED12 [23, 24].
The aim of this study was to examine the frequency of
known genetic leiomyoma driver alterations in histo-
pathological UL subtypes and ULMSs to scrutinize
molecular variability in these tumors and to identify a
potential UL subtype(s) that resembles ULMSs. The
study material consisted of a comprehensive series of 94
histopathological UL variants (incl. leiomyomas with
bizarre nuclei, cellular, and mitotically active leiomyo-
mas), 51 ULMSs, and 65 conventional ULs as controls.
MED12 mutation status was analyzed by direct sequen-
cing, while HMGA2 overexpression and biallelic FH
inactivation were determined by immunohistochemistry.
Methods
Samples
A retrospective series of 210 archival formalin-fixed
paraffin-embedded (FFPE) samples representing various
uterine smooth muscle tumors was collected at the De-
partment of Pathology, Hospital District of Helsinki and
Uusimaa, Helsinki, Finland, after which the samples
were anonymized for the study. The series included 65
conventional, 51 cellular (22 cellular and 29 highly cellu-
lar), and 25 mitotically active leiomyomas (11 lesions
showing simultaneously increased cellularity), 18 leio-
myomas with bizarre nuclei, and 51 leiomyosarcomas.
Histological evaluation
Histological assessment of each specimen was performed
by a pathologist specialized in gynecological pathology (RB)
and the tumors were classified into conventional, cellular,
highly cellular, and mitotically active leiomyomas, leiomyo-
mas with bizarre nuclei, and ULMSs according to the
WHO criteria [4] (see Additional file 1: Table S1). The
microscopic morphology of highly cellular leiomyoma may
mimic endometrial stromal tumor. In ambiguous cases, the
differential diagnosis was aided by smooth muscle actin,
desmin, h-caldesmon (smooth muscle markers), and CD-
10 (relative endometrial stromal cell marker) immuno-
histochemistry. For DNA extraction and tissue microarray
(TMA) construction, pathologist marked representative
tumor regions of each sample.
DNA extraction and tissue microarray construction
Genomic DNA was extracted either with NucleoSpin® FFPE
DNA Kit, NucleoSpin® FFPE RNA/DNA Kit (Macherey-
Nagel, Düren, Germany), or with a conventional non-
enzymatic method [25]. Quadruplicate 0.8 mm cores of
FFPE tumor tissue from each case were punched with a
manual tissue arrayer (MTA-I, Beecher Instruments, Sun
Prairie, WI, USA) to an empty paraffin block. Cores of
FFPE myometrium tissue were also incorporated in the
TMA block as internal controls.
MED12 mutation analysis
MED12 mutation screening of exons 1 and 2 was per-
formed by direct sequencing. Exon 2, which harbors the
great majority of mutations, was analyzed first and if nega-
tive, mutation screening was extended to exon 1. MED12
exon 2 mutation status has been previously reported for
64 out of 65 conventional ULs, 91 out of 94 histopatho-
logical UL variants, and 19 out of 51 ULMSs [12, 24, 26],
and exon 1 for all MED12 exon 2 mutation-negative con-
ventional ULs (n = 28) [26] and histopathological UL
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variants (n = 77) [27]. The primer sequences and condi-
tions have been previously described [12, 27]. Sequencing
was carried out using Big Dye Terminator v3.1 sequencing
chemistry (Applied Biosystems, Foster City, CA, USA) on
an ABI3730 automatic DNA Sequencer according to the
manufacturer’s instructions. The sequence graphs were
analyzed both manually and with Mutation Surveyor soft-
ware (SoftGenetics, State College, PA, USA). MED12
NM_005120.2 was used as a reference sequence. MED12
mutation screening was successful in 98.6% (207/210) of
the samples for exon 2 and in 95.2% (138/145) for exon 1.
The three samples which failed in direct sequencing of
exon 2 showed clearly visible larger deletions on an agar-
ose gel (see Additional file 2: Figure S1).
Immunohistochemistry
HMGA2 overexpression and biallelic FH inactivation
were assessed by immunohistochemistry. Biallelic inacti-
vation of FH was detected with 2-succinocysteine (2SC)
staining, which is based on the recognition of modified
(succinated) proteins formed in FH-deficient cells as a
result of the accumulation of fumarate [28, 29]. 2SC
status has been previously reported for all 65 conven-
tional ULs [26]. Heat-induced antigen retrieval was
carried out in a microwave using citrate buffer (pH 6.0).
Endogenous peroxidase blocking was followed by over-
night incubation with the primary antibody at 4 °C (anti-
HMGA2 1:2000, Biocheck Inc., Foster City, CA, USA;
anti-2SC 1:2000 [29]). A positive reaction for HMGA2 and
2SC was detected by DAB Plus Substrate System (Thermo
Fisher Scientific, Waltham, MA, USA) or EnVision + kit
(Dako, Carpinteria, CA, USA), respectively.
Scoring of the TMAs
Immunohistochemical scoring was carried out by a
pathologist (RB). For both HMGA2 and 2SC, the intensity
of the immunoreaction was classified into four groups:
- = fully negative, (+) = single cell positivity, + = low posi-
tivity, ++ = strong positivity (see Additional file 3: Figure
S2). Only samples that showed strong positivity in the im-
munoreaction were considered positive. For 2SC, the posi-
tive staining indicated accumulation of fumarate and
succinated proteins, and thus biallelic inactivation of FH,
while the negative staining indicated that the cells retained
sufficient amount of FH. For HMGA2, only nuclear label-
ling of the protein was evaluated.
FH mutation analysis
Tumors showing 2SC positivity (n = 10) were directly se-
quenced for FH mutations. The sequencing was carried
out as described above in MED12 mutation analysis. FH
NM_000143.3 was used as a reference sequence. FH exon
1 was excluded from the mutation screening. Two out of
ten 2SC-positive tumors, both representing ULMSs,
did not amplify at all and were thus excluded from
the mutation screening.
Statistical analyses
Statistical analyses were performed using R software, ver-
sion 2.14.0 (R Foundation for Statistical Computing,
Vienna, Austria, www.r-project.org). Fisher’s exact test was
used to compare the frequency of MED12 mutations, pres-
ence of HMGA2 overexpression and biallelic FH inactiva-
tion between conventional ULs and histopathological UL
subtypes or ULMSs. Eleven mitotically active leiomyomas
with increased cellularity were included in both mitotically
active and cellular/highly cellular leiomyoma subtypes
for statistical testing. All P-values were two-sided and
P-value <0.05 was considered statistically significant.
Findings
Uterine smooth muscle tumor classification
Based on the number of mitotic figures per 10 high
power fields, severity of nuclear atypia (0–3), degree of
cellularity (normal, cellular, highly cellular), and presence
of tumor necrosis in the hematoxylin-eosin-stained sec-
tions of the tumor specimens, the samples were classi-
fied into 65 conventional, 51 cellular (22 cellular and 29
highly cellular), and 25 mitotically active leiomyomas (11
lesions showing simultaneously increased cellularity), 18
leiomyomas with bizarre nuclei, and 51 leiomyosarcomas
(see Additional file 4: Figure S3).
Conventional leiomyomas
MED12 and HMGA2 alterations accounted for the vast
majority of conventional ULs (53/65, 81.5%) (Table 1, Fig. 1,
see Additional file 5: Table S2), which is in line with previ-
ous literature [11]. The third driver alteration, biallelic FH
inactivation, is known to be very rare in sporadic conven-
tional ULs [15, 26, 30, 31]. Accordingly, all conventional
ULs included in this study were FH proficient [26]. This set
of conventional ULs provides thus an appropriate reference
series for the other tumor types in this study.
Histopathological uterine leiomyoma subtypes
As previously reported, the histopathological UL variants
(18.1%, 17/94) harbored significantly fewer MED12 mu-
tations than the conventional leiomyomas (56.9%, 37/65;
P = 5.2 × 10−7) [12] (Table 1, see Additional file 5: Table
S2 and Additional file 6: Table S3). No significant differ-
ence was seen in the number of HMGA2 overexpressing
tumors between histopathological UL variants (13.8%, 13/
94) and conventional leiomyomas (Table 1, see Additional
file 5: Table S2 and Additional file 6: Table S3). Unlike
conventional leiomyomas, the histopathological UL vari-
ants (8.5%, 8/94) displayed 2SC positivity as a sign of FH
deficiency (Table 1, Fig. 1, see Additional file 5: Table S2
and Additional file 6: Table S3).
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Mitotically active leiomyomas
Mitotically active ULs occur primarily in premenopausal
women. Tumors display an increased number of mitotic
figures per 10 high power fields, but otherwise present
macroscopic and histologic appearances of conventional
leiomyomas, lacking cytological atypia and tumor cell
necrosis [32, 33]. Hormonal and other external factors
in the tumor microenvironment have been associated
with this tumor type and are thought to contribute to
the elevated number of mitoses. For example, mitotically
active ULs are usually diagnosed during the secretory
phase of the menstrual cycle [34] and patients using
progestin display significantly higher mitotic activity in
their leiomyomas compared to control patients [35]. The
known leiomyoma driver alterations were observed in 40%
of the tumors:MED12 mutation frequency was slightly, but
not significantly, lower in mitotically active ULs (36%, 9/25)
compared to conventional leiomyomas (Table 1, Fig. 1, see
Additional file 5: Table S2 and Additional file 6: Table S3).
Other alterations were very rare as only one tumor showed
HMGA2 overexpression (4%) and none displayed biallelic
FH inactivation (Table 1, Fig. 1, see Additional file 6:
Table S3). Our results suggest that the molecular
background of mitotically active ULs slightly differs
from that of conventional ULs.
Cellular leiomyomas
Cellular leiomyomas present clearly increased cellularity
when compared to the surrounding myometrium, lack
nuclear atypia and tumor necrosis, and have infrequent
mitotic figures [36]. The tumors commonly have an
irregular border that merges with the surrounding myo-
metrium. Cytogenetically, these tumors have been shown
to display loss of the short arm of chromosome 1, and
their transcriptional profile has been suggested to be more
similar to leiomyosarcomas than conventional leiomyo-
mas or normal myometrium [37]. Additionally, two small
clinical series have reported cellular leiomyomas to as-
sociate with aggressive clinical behavior [38, 39]. Based
on our results, the most common driver alteration in
cellular ULs is HMGA2 overexpression, which was seen
in one third of the tumors (32%, 8/25) (Table 1, Fig. 1,
see Additional file 6: Table S3). This was the highest
frequency of HMGA2 overexpression in any tumor type
studied. The difference was statistically significant when
Table 1 MED12 mutations, HMGA2 aberrations, and biallelic FH inactivation in uterine smooth muscle tumors
Smooth muscle tumor subtype Total MED12 mutation positive HMGA2 overexpressing FH deficient
N % P-value 95% CI N % P-value 95% CI N % P-value 95% CI
Conventional 65 37 56.9 16 24.6 0 0
Histopathological UL variant 94 17 18.1 5.2 × 10−7 2.76–13.14 13 13.8 0.10 0.83–5.01 8 8.5 0.02 0.00–0.81
Mitotically active 25 9 36 0.10 0.83–6.93 1 4 0.03 1.07–341.56 0 0
Leiomyoma with bizarre nuclei 18 3 16.7 3.0 × 10−3 1.61–38.18 0 0 0.02 1.24- ∞ 6 33.3 4.9 × 10−5 0.00–0.19
Cellular 25 4 16 7.3 × 10−4 1.98–30.31 8 32 0.60 0.23–2.23 1 4 0.28 0.00–15.00
Highly cellular 37 3 8.1 6.0 × 10−7 3.98–81.73 4 10.8 0.12 0.77–11.96 1 2.7 0.36 0.00–22.20
Leiomyosarcoma 51 11 21.6 1.4 × 10−4 1.96–12.16 3 5.9 0.01 1.35–29.40 2 3.9 0.19 0.00–4.16
Eleven mitotically active leiomyomas with increased cellularity were included in both mitotically active and cellular/highly cellular leiomyoma subtypes for
statistical testing
Fig. 1 Mutation spectra of uterine smooth muscle tumors. The
frequencies of MED12 mutations, HMGA2 aberrations, and biallelic FH
inactivation in conventional ULs a, histopathological UL variants b-e,
and ULMSs f. Eleven mitotically active leiomyomas with increased
cellularity were included in both mitotically active and cellular/highly
cellular leiomyoma subtypes
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compared to mitotically active ULs, leiomyomas with bi-
zarre nuclei, or ULMSs. The MED12 mutation frequency
in these tumors was rather low: 16% (4/25) (Table 1, Fig. 1,
see Additional file 6: Table S3). Also one cellular UL that
presented 2SC positivity (4%) and harbored a potential FH
mutation in exon 3 (c.321_323del3, p.N107_Q108delinsL)
was identified. This three base pair deletion results in the
substitution of amino acids N107 and Q108 with leucine
(L). Missense mutation affecting the same amino acid
(c.320A > C, p.N107T) has been reported in six UK
HLRCC families [14], supporting the pathogenicity of the
mutation. Overall, the leiomyoma driver alterations were
observed in more than half of the cellular ULs (52%, 13/
25), but their distribution differed from that observed in
conventional tumors.
Highly cellular leiomyomas
Highly cellular leiomyomas are characterized with even
higher density of cells reminiscent of endometrial stromal
tumors, and may be occasionally misdiagnosed as endo-
metrial stromal nodules when well circumscribed [36, 40].
Here, these tumors harbored the lowest number of
MED12 mutations of all tumor types analyzed (8.1%, 3/
37) (Table 1, Fig. 1, see Additional file 6: Table S3). Four
tumors overexpressed HMGA2 (10.8%) and one showed
2SC positivity (2.7%). Overall, this tumor subtype dis-
played the least amount of leiomyoma driver alterations
(21.6%, 8/37) suggesting that there are other, still un-
known factors underlying the genesis of these lesions.
Leiomyomas with bizarre nuclei
Leiomyomas with bizarre nuclei (previously termed
‘atypical leiomyomas’) are characterized by the presence of
large cells with eosinophilic cytoplasm and bizarrely
shaped, multilobated or -nucleated nuclei. Low mitotic ac-
tivity and lack of tumor cell necrosis are also typical for
these tumors [41, 42]. Interestingly, as many as one third
of ULs with bizarre nuclei (33.3%, 6/18; P = 4.9 × 10−5)
displayed 2SC positivity, indicating biallelic FH inactiva-
tion (Table 1, Fig. 1, see Additional file 6: Table S3). Subse-
quently, our sequencing efforts identified an FH mutation
in two of the tumors. One mutation, c.587A > G,
p.H196R, has been previously reported in three Finnish
HLRCC families [30, 43] and in three isolated cases. The
germline origin of the mutation was confirmed also for
the patient in this study. Altogether six patients in these
previously identified families have been diagnosed with
renal cell cancer. Another tumor with bizarre nuclei had a
mutation, c.739-2A > C in exon-intron junction preceding
exon 6, which likely affects splicing. FH deficiency has
been shown to be overrepresented in leiomyomas with bi-
zarre nuclei and some of the morphologic features typical
for these tumors have been associated with FH mutations
[42, 44–47]. Even though morphologic features alone lack
robustness to separate sporadic and HLRCC-associated
ULs [48–50], the possibility of an underlying germline FH
mutation should be considered in patients with ULs with
bizarre nuclei. Clinical features such as the severity of
symptoms, number of tumors within the uterus, age at
diagnosis, and possible family history of ULs can be evalu-
ated, and patients should be examined for possible cutane-
ous leiomyomas. Should additional features suggestive of
HLRCC be identified, individuals could be directed to
genetic counselling and molecular screening. Subse-
quently, mutation-positive individuals could be informed
on the possible negative effects of HLRCC on fertility, and
offered appropriate screening program for renal cell
cancer. On the other hand, FH deficiency can also be a
somatic event in ULs and may not exclusively indicate
HLRCC syndrome, although somatic biallelic FH inactiva-
tion has only rarely been reported [31, 50]. The most
prevalent alterations in conventional ULs were only rarely
observed in leiomyomas with bizarre nuclei: MED12
mutations were identified in three out of 18 tumors
(16.7%) and none displayed HMGA2 overexpression
(Table 1, Fig. 1, see Additional file 6: Table S3). Recently, it
has been suggested that leiomyomas with bizarre nuclei
can be divided into two subtypes based primarily on
nuclear features; some tumors show significantly higher
rates of HMGA2 immunoreactivity and frequent MED12
mutations and the others may occasionally be related to
FH mutations [51]. The high frequency of FH inactivation
and the low frequency of MED12 and HMGA2 alterations
distinctly separates these tumors from conventional ULs,
other histopathological UL variants, and ULMSs.
Uterine leiomyosarcomas
Leiomyosarcomas are diagnosed primarily based on cyto-
logical atypia, mitotic activity, and tumor cell necrosis,
which distinguishes them from benign uterine smooth
muscle tumors [52]. Despite well-defined morphological
criteria, diagnostic challenges emerge, at times, in daily
pathological practice in differentiating ULMSs from histo-
pathological UL subtypes. Leiomyosarcomas are known to
harbor complex numerical and structural chromosomal ab-
errations, as well as mutations in well-known cancer genes
ATRX, TP53, and RB1 [23, 24, 53]. As previously reported,
MED12 mutations were one of the most common alter-
ations in ULMSs (21.6%, 11/51), though significantly less
frequent than in conventional ULs (P = 1.4 × 10−4) (Table
1, Fig. 1, see Additional file 5: Table S2 and Additional file
7: Table S4). [24, 26, 54]. Also HMGA2 overexpression was
infrequent compared to conventional ULs (5.9%, 3/51,
P = 0.01) and two tumors showed biallelic FH inactivation
(3.9%). Although not as common as in conventional ULs,
leiomyoma driver alterations were observed in nearly one
third of ULMSs (31.4%, 16/51). This suggests that some
ULMSs may originate from a leiomyoma precursor, or that
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the UL driver alterations provide a growth advantage also
for these malignant smooth muscle tumors. The progres-
sion from a benign UL precursor to a malignant leiomyo-
sarcoma has been proposed also previously based on
microscopically visible co-localization of morphologically
benign areas within ULMS [13, 55–57]. Furthermore, in
some of these cases, identical MED12 mutations have been
identified in both components [13]. Of note, one leiomyo-
sarcoma FFPE block in our sample series showed simultan-
eous co-localization of a leiomyoma with bizarre nuclei. In
this case, both tumors were wild type for all leiomyoma
driver alterations.
Mutual exclusivity
Altogether 65 uterine smooth muscle tumors harbored
MED12 mutations, 32 showed HMGA2 overexpression,
and ten 2SC positivity, indicating biallelic FH inactiva-
tion. None of the tumors displayed simultaneously more
than one leiomyoma driver alteration, indicating that
MED12 mutations, HMGA2 overexpression, and biallelic
FH inactivation are mutually exclusive (Fig. 2).
Limitations of the study
The differentiation of uterine smooth muscle tumors may
occasionally result in ambiguous cases, which are challen-
ging to diagnose. Although the sample series in this study
was large, considering the rarity of histopathological UL
subtypes and ULMSs, the classification of tumors based
on the leiomyoma driver alterations resulted in rather
small subgroups. Also no clinical data were available
for the samples. In the future, it would be interesting to
study the associations between different tumor sub-
groups and clinical characteristics in an even larger set
of samples. In addition, the fairly modest success rate of
FH screening may be due to the low quantity and subopti-
mal quality of FFPE samples, or there might be other
kinds of variations that contribute to the genesis of these
lesions, such as larger deletions, insertions, or more com-
plex structural alterations, which are not detectable by
amplicon sequencing, or alternatively the alterations may
be epigenetic or affect non-coding regulatory regions.
Conclusions
To conclude, 107 out of 210 uterine smooth muscle
tumors analyzed harbored one of the three leiomyoma
driver alterations. No tumor displayed more than one
change, confirming the previous observations [12, 16,
26, 58] that these mutations are mutually exclusive
driver alterations. While these alterations were identi-
fied in various UL subtypes, their relative frequencies
varied considerably. Of particular interest was the high
frequency of FH-deficient tumors among leiomyomas
with bizarre nuclei; although not an unambiguous
indicator for HLRCC, the possibility of this highly
penetrant tumor predisposition syndrome should be
considered and additional suggestive clinical charac-
teristics evaluated when these tumors are encountered
at the clinic. Except for conventional ULs, a significant
proportion of all other UL subtypes displayed no
driver alterations and additional work is required to
reveal the underlying causes in these mutation-
negative tumors. Finally, nearly one third of ULMSs
displayed one of the three UL driver alterations, em-
phasizing the role of these aberrations also in the
ULMS tumorigenesis. It is clinically relevant to under-
stand the molecular mechanisms driving the tumori-
genesis of uterine smooth muscle tumors, as it may
lead to improved diagnosis and personalized medical
treatments in the future.
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Additional file 1: Table S1. Histopathological features of 210 uterine
smooth muscle tumors (XLSX 19 kb).
Additional file 2: Figure S1. Large deletions in MED12 exon 2. Three
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Fig. 2 Mutual exclusivity of MED12 mutations, HMGA2
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cellular leiomyoma with HMGA2 overexpression, c 2SC-positive
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shown with ×40 magnification
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